Publications by authors named "N Boissel"
Article Synopsis
- - In the last decade, significant advancements have been made in treating adults with newly diagnosed B-cell acute lymphoblastic leukaemia, driven by better understanding of the disease and innovative treatment strategies like incorporating immunotherapy and tyrosine kinase inhibitors.
- - Despite these advancements, adults still have worse outcomes compared to children, facing higher rates of treatment failure and complications, leading to ongoing use of transplant consolidation for high-risk cases.
- - The article emphasizes the need for new trial designs to further improve treatment strategies and personalize care for adults with acute lymphoblastic leukaemia, sharing insights from practices across Europe and other continents.
This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and to describe the latest clinical research using the bispecific T-cell-engaging immunotherapy blinatumomab in the first-line treatment setting. Current standard-of-care chemotherapeutic backbones for newly diagnosed Ph-negative BCP-ALL are based on the same overarching treatment principle: to reduce disease burden to undetectable levels and maintain lasting remission. The adult treatment landscape has progressively evolved following the adoption of pediatric-inspired regimens.
View Article and Find Full Text PDFPurpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.
Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).